Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
The complement system provides critical immunoprotective and immunoregulatory functions but uncontrolled complement activation can lead to severe pathology. In the rare hemolytic disease paroxysmal nocturnal hemoglobinuria (PNH), somatic mutations result in a deficiency of glycosylphosphatidylinositol-linked surface proteins, including the terminal complement inhibitor CD59, on hematopoietic stem cells. In a dysfunctional bone marrow background, these mutated progenitor blood cells expand and populate the periphery. Deficiency of CD59 on PNH red blood cells results in chronic complement-mediated intravascular hemolysis, a process central to the morbidity and mortality of PNH. A recently developed, humanized monoclonal antibody directed against complement component C5, eculizumab (Soliris; Alexion Pharmaceuticals Inc., Cheshire, CT, USA), blocks the proinflammatory and cytolytic effects of terminal complement activation. The recent approval of eculizumab as a first-in-class complement inhibitor for the treatment of PNH validates the concept of complement inhibition as an effective therapy and provides rationale for investigation of other indications in which complement plays a role.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Eculizumab exemplifies a more extreme case. It binds human complement component C5 with high affinity but does not cross-react with rodent C5. Conventional rodent PK and pharmacology studies are therefore essentially uninformative regarding target engagement.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [53]
Citations
Cites
1 retracted
The structure of complement C3b provides insights into complement activation and regulation
Ajees, A. A., Gunasekaran, K., Volanakis, J. E., Narayana, S. V. L., Kotwal, G. J., & Murthy, H. M. K. (2006) · Nature · doi:10.1038/nature05258 · Cited by 70
RetractedHematology: Basic Principles and Practice
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-3-238_2 · Cited by 1,857
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Rother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Walport, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104123441506 · Cited by 1,481
ENDOGENOUS NITRIC OXIDE INHIBITS HUMAN PLATELET ADHESION TO VASCULAR ENDOTHELIUM
Radomski, M. W., Palmer, R. M. J., & Moncada, S. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91481-4 · Cited by 1,437
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Young, N. S., Schubert, J., Brodsky, R. A., Socié, G., Muus, P., Röth, A., Szer, J., Elebute, M. O., Nakamura, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061648 · Cited by 1,303
Radomski, M. W., Palmer, R. M. J., & Moncada, S. (1987) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1987.tb11367.x · Cited by 1,164
Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., Takahashi, M., Kitani, T., & Kinoshita, T. (1993) · Cell · doi:10.1016/0092-8674(93)90250-t · Cited by 1,029
Generation of C5a in the absence of C3: a new complement activation pathway
Huber-Lang, M., Sarma, J. V., Zetoune, F. S., Rittirsch, D., Neff, T. A., McGuire, S. R., Lambris, J. D., Warner, R. L., Flierl, M. A., Hoesel, L. M., et al. (2006) · Nature Medicine · doi:10.1038/nm1419 · Cited by 975
Research works printed but not linked: 4
- Male, D., Brostoff, J., Roth, D. & Roitt, I. Immunology (Mosby-Elsevier, Philadelphia, 2006).
- Jain, R.I., Moreland, L.W., Caldwell, J.R., Rollins, S.A. & Mojcik, C.F. A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 42, S77 (1999).
- Tesser, J. et al. Safety and efficacy of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 44, S274 (2001).
- Rotoli, B. & Luzzatto, L. Paroxysmal nocturnal hemoglobinuria. Semin. Hematol. 26, 201–207 (1989).
Cited by
Items 601–700 of 780
Shimizu, S., Morohashi, T., Kanezawa, K., Yagasaki, H., Takahashi, S., & Morioka, I. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.908183 · Cited by 2
“Eculizumab is a humanized monoclonal antibody to complement protein C5 that can prevent tissue damage by inhibiting the formation of C5b-9 as a treatment for PNH and atypical hemolytic uremic syndrome (18).”
BackgroundNording, H., Baron, L., Lübken, A., Emami, H., von Esebeck, J., Meusel, M., Sadik, C. D., Schanze, N., Duerschmied, D., Köhl, J., et al. (2023) · TH Open · doi:10.1055/a-2156-8048 · Cited by 2
Ninan, G. A., Angel Miraclin, T., Karumathil, S., Prasad, J. D., Kumar, S. P., Bal, D., Nair, A. V., Ahmed, S. A. I., Thirumal, P. A., George, B., et al. (2023) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2023.107305 · Cited by 2
Duan, H., Abram, T. G., Cruz, A. R., Rooijakkers, S. H. M., & Geisbrecht, B. V. (2023) · ImmunoHorizons · doi:10.4049/immunohorizons.2300064 · Cited by 2
Shangguan, W., Li, X., Wang, Y., Huang, Z., Dong, Y., Feng, M., & Feng, J. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00126 · Cited by 2
Development and application of UHPLC-MS/MS method to quantify eculizumab in PNH patients
Zhang, Z., Sheng, N., Liu, X., Han, B., Zhang, B., & Zhang, J. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.116740 · Cited by 2
Validation for soluble C5b-9 detection and comparative analysis of three quantification methods
Profaizer, T., Saadalla, A. M., & Nandakumar, V. (2025) · Journal of Immunological Methods · doi:10.1016/j.jim.2025.113882 · Cited by 2
Firdaus, N. H. W., Mallick, B., Nandakumar, K. S., & Shakya, A. K. (2025) · Journal of The Royal Society Interface · doi:10.1098/rsif.2025.0138 · Cited by 3
“Eculizumab is the first approved antagonist (C5 inhibitor) that binds specifically to C5, blocking its cleavage [66].”
Paroxysmal Nocturnal Hemoglobinuria
Tublin, M., Nelson, J. B., Borhani, A. A., Furlan, A., Heller, M., & Squires, J. (2020) · Handbook of Hematologic Malignancies · doi:10.1016/b978-0-323-35762-3.00031-7 · Cited by 343
Nishidate, M., Shibahara, N., Hayasaka, A., Staack, R. F., Miyayama, T., Terao, K., & Jordan, G. (2022) · Bioanalysis · doi:10.4155/bio-2022-0116 · Cited by 2
Complement inhibition for paroxysmal nocturnal hemoglobinuria: where we stand and where we are going
Risitano, A. M. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1041376 · Cited by 2
“Eculizumab (Soliris , Alexion, Cheshire, CT, US) is an anti-complement component 5 (C5) humanized mAb [3], which binds to C5 thereby preventing its cleavage into C5a and C5b; thus, eculizumab disables the complement cascade at the level of C5, eventually preventing the formation of the membrane attack complex (MAC), t…”
BackgroundEffective eculizumab therapy followed by BMT in a boy with paroxysmal nocturnal hemoglobinuria
Oshiro, H., Goi, K., Akahane, K., Inukai, T., & Sugita, K. (2015) · Pediatrics International · doi:10.1111/ped.12522 · Cited by 2
Complement Regulators and Inhibitors in Health and Disease: A Structural Perspective
Yatime, L., Bajic, G., Schatz-Jakobsen, J. A., & Andersen, G. R. (2016) · Advances in delivery science and technology · doi:10.1007/978-1-4939-3634-2_2 · Cited by 2
Clinical Effects of Eculizumab in PNH: Extravascular Hemolysis After Eculizumab Treatment
Notaro, R., & Risitano, A. M. (2017) · Springer eBooks · doi:10.1007/978-4-431-56003-6_17 · Cited by 2
The promising expedition of the delivery systems for monoclonal antibodies
Megahed, M. A., El‐Sawy, H. S., & El‐Say, K. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819666-3.00003-1 · Cited by 3
Willrich, M. A. V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815499-1.00023-5 · Cited by 3
Membranoproliferative Glomerulonephritis and C3 Glomerulopathy in Children
Licht, C. P. B., Vivarelli, M., Khursigara, M. R., Pickering, M. C., & Walker, P. D. (2021) · Springer eBooks · doi:10.1007/978-3-642-27843-3_29-2 · Cited by 2
Treatment and Management of Autoimmune Neuropathies
El-Abassi, R. N., Soliman, M. Y., Levy, M. H., & England, J. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-71317-7.00015-9 · Cited by 2
Fundamental technologies for antibody engineering
(2012) · Elsevier eBooks · doi:10.1533/9781908818096.57 · Cited by 3
Laber, D. A., Patel, P. C., Logothetis, C., Patel, A. K., Jaglal, M. V., Haider, M., Visweshwar, N., Rathnakumar, G., & Eatrides, J. M. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14136 · Cited by 2
Chen, Y., Liu, H., Wang, C., Chen, W., Li, L., Wu, J., Wang, G., Ling, G. S., & Fu, R. (2024) · British Journal of Haematology · doi:10.1111/bjh.19477 · Cited by 2
“4,5 Patients can only benefit during treatment, and once the drug is stopped, the patients will once again under haemolysis, the degree of which corresponding to the size of PNH clones.”
BackgroundInflammation in the Pathogenesis of Progressive Retinal Dystrophies
Hollingsworth, T. (2021) · Journal of Ophthalmic Research and Vision Care · doi:10.54289/jorvc2100103 · Cited by 3
Therapeutic Antibodies in Clinical Use and Leading Clinical Candidates
Zhang, N., Williams, B. R., Lü, P., An, Z., & Chin, C. (2009) · Wiley eBooks · doi:10.1002/9780470485408.ch31 · Cited by 2
“It retained the similar binding affinity to human C5 (KD 1⁄4 120 pM) of the parental murine antibody (Rother et al. 2007).”
BackgroundParoxysmal Nocturnal Haemoglobinuria
Hillmen, P. (2010) · doi:10.1002/9781444323160.ch11 · Cited by 2
Protein Engineering: Applications to Therapeutic Proteins and Antibodies
Popplewell, A. G. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse537 · Cited by 2
Mechanism of Action for Therapeutic Antibodies
Zhou, Y., & Marks, J. D. (2016) · Wiley eBooks · doi:10.1002/9781118940648.ch3 · Cited by 3
Therapeutic complement modulation for hematological diseases: Where we stand and where we are going
Risitano, A. M. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.05.012 · Cited by 2
Editorial: Complement and Immunotherapeutics
Okrój, M., & Volokhina, E. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663459 · Cited by 2
“Additional interest in complement as an effector mechanism of therapeutic antibodies appeared when rituximab, the first antitumor antibody, was introduced into the clinics in 1997 (4) and a decade later when the first complement-specific drug, eculizumab was approved (5).”
BackgroundPregnancy in Paroxysmal Nocturnal Hemoglobinuria
Miyasaka, N., & Miura, O. (2017) · Springer eBooks · doi:10.1007/978-4-431-56003-6_21 · Cited by 1
Disease-Specific Treatment for Primary Membranous Nephropathy: The Role of Monoclonal Antibodies
Ruggenenti, P. L., & Remuzzi, G. (2023) · Medical Research Archives · doi:10.18103/mra.v11i3.3601 · Cited by 1
Cheng, W. Y., Fishman, J., Yenikomshian, M. A., Mahendran, M., Kunzweiler, C. P., Vu, J. D., & Duh, M. S. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02725-5 · Cited by 1
“In 2007, the complement factor 5 (C5) inhibitor eculizumab became the standard of care for PNH in the USA [8–10].”
Tufan, A. K., Batibay, F. O., Aksoy, G. K., Gülhan, B., Kılıç, B. D., Dursun, İ., Büyükkaragöz, B., Yılmaz, A. Ç., Nalçacıoğlu, H., Becerir, T., et al. (2024) · Children · doi:10.3390/children11101164 · Cited by 1
“…is a recombinant humanized chimeric anti-C5 monoclonal antibody, which binds to complement C5, preventing C5 cleavage and the formation of C5a and C5b-9, thus blocking the C5a pro-inflammatory and C5b-9 (terminal membrane attack complex) pro-thrombotic consequences of complement activation [5–7].”
BackgroundNovel drug delivery system in the management of myasthenia gravis
Yadav, M., Kumar, R., & Kumar, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13474-6.00004-4 · Cited by 1
General Principles of Immunotherapy in Neurological Diseases
Rommer, P. S., Hecker, M., Zrzavy, T., & Zettl, U. K. (2024) · Springer eBooks · doi:10.1007/978-3-031-60006-7_12 · Cited by 1
Wang, C., Wang, Y., Duan, Y., Dong, Y., Hua, H., Cui, H., Huang, S., Huang, Z., Lu, J., Ding, C., et al. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00108 · Cited by 1
Kalantari, A., Karimizadeh, Z., Jafari, L., Behfar, M., & Hamidieh, A. A. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2673-4266 · Cited by 1
Establishment of a Time-Resolved Fluoroimmunoassay for sC5b-9 and Validation in Lupus Nephritis
Wu, B., Zhu, L., Kao, S., Bao, H., Zheng, T., Qin, Y., Shao, X., Huang, B., & Zhao, H. (2025) · Journal of Fluorescence · doi:10.1007/s10895-025-04620-4 · Cited by 1
Evaluating inebilizumab in the treatment of generalized myasthenia gravis
Carbunar, O. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2594349 · Cited by 2
Manso, T., Sanou, G., Nousias, C., Maalem, I., Boutin, F., Giudicelli, V., Duroux, P., Lefranc, M., & Κοσσίδα, Σ. (2025) · mAbs · doi:10.1080/19420862.2025.2594260 · Cited by 2
“67”
Bracke, L., Olesen, H. G., Pannecoucke, E., Delahaye, T., Persson, E. K., Blanchetot, C., de Haard, H., Hack, C. E., Andersen, G. R., & de Walle, I. V. (2026) · mAbs · doi:10.1080/19420862.2026.2666430 · Cited by 1
Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles
Mannes, M., Zelek, W. M., & Trouw, L. A. (2026) · European Journal of Immunology · doi:10.1002/eji.70231 · Cited by 2
“Afterwards, humanization was performed for clinical use [ 19–21 ].”
Guo, Q., Wang, C., Mauduit, V., Stukalov, A., Mohebnasab, M., Sagar, A., Vikman, S., Williams, S. H., Maden, B. E. H., Eitan, T., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04511-6 · Cited by 4
“In xenotransplantation, efforts to limit human complement-dependent cytotoxicity have included complement inhibitors such as pegcetacoplan 50 and eculizumab 51 , together with gene-edited pigs expressing human complement-regulatory transgenes 23 .”
V. Paroxysmal Nocturnal Hemoglobinuria: The Pathophysiology and the Current Treatment
Ueda, Y., & Nishimura, J. (2015) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.104.1397 · Cited by 1
Paroksysmal nattlig hemoglobinuri ved Oslo universitetssykehus 2000 – 10
Nissen‐Meyer, L. S. H., Tjønnfjord, G. E., Gołębiowska, E., Kjeldsen‐Kragh, J., & Akkök, Ç. A. (2015) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.14.0444 · Cited by 1
Sikuyayenga, M. J., & Karlin, N. J. (2012) · Cancer and Clinical Oncology · doi:10.5539/cco.v2n1p1 · Cited by 1
Eculizumab treatment of atypical hemolytic uremic syndrome
Kaplan, B. S., Ruebner, R. L., & Copelovitch, L. A. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.750579 · Cited by 1
“This blocks the proinflammatory and cytolytic effects of terminal complement activation [1].”
BackgroundHorvath, C. J., Holers, V. M., Fridkis‐Hareli, M., Storek, M., Mazsaroff, I., Risitano, A. M., & Lundberg, A. S. (2013) · Cited by 1
Kato, T., Matsukawa, H., Shiozaki, S., Fuji, T., Fujiwara, Y., & Ninomiya, M. (2015) · Okayama Igakkai Zasshi (Journal of Okayama Medical Association) · doi:10.4044/joma.127.35 · Cited by 1
Complement and Complement Regulatory Proteins in Diabetes
Halperin, J. A., Ghosh, P., Chorev, M., & Vaidya, A. (2015) · Springer eBooks · doi:10.1007/978-3-319-21927-1_2 · Cited by 1
Soliris (Eculizumab): Discovery and Development
Lambert, M. A., & Finlay, W. J. J. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782624202-00401 · Cited by 1
Overview of Therapy for Glomerular Disease
Cattran, D., & Reich, H. N. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10033-8 · Cited by 1
Significance of Complement Activation in Alzheimer’s Disease
Loeffler, D. A. (2008) · touchREVIEWS in Neurology · doi:10.17925/usn.2008.04.02.52 · Cited by 1
Clinical Effects of Eculizumab in PNH: Poor Responders to Eculizumab
Nishimura, J., Kinoshita, T., & Kanakura, Y. (2017) · Springer eBooks · doi:10.1007/978-4-431-56003-6_18 · Cited by 1
Ramírez, J. I., Gómez, E. D., Campos, M. C. A., Puerto, R., & Córdoba, J. P. (2017) · Revista Colombiana de Nefrología · doi:10.22265/acnef.4.1.267 · Cited by 2
Schubert, J. E. A., & Menne, J. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1307104 · Cited by 1
Monoclonal Antibodies as Therapeutic Agents
Khan, M. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-30273-7_5 · Cited by 1
Tridente, G. (2013) · Springer eBooks · doi:10.1007/978-88-470-5313-7_18 · Cited by 1
Antibody Fc engineering for optimal antibody performance
(2012) · Elsevier eBooks · doi:10.1533/9781908818096.225 · Cited by 3
Cataldi, M., & Cavaccini, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99417-0 · Cited by 1
Cataldi, M., & Cavaccini, A. (2010) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.64509-x · Cited by 1
Sayegh, M. H., & Chandraker, A. K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10070-3 · Cited by 2
Mollnes, T. E. (2013) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.52-3_ltoe · Cited by 1
Wu, H. H., Crames, M., Wei, Y., Liu, D., Gueneva-Boucheva, K., Son, I., Frego, L., Han, F., Kroe‐Barrett, R., Nixon, A. E., et al. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.06.014 · Cited by 1
Diagnostic Challenges in Thrombotic Microangiopathies
Bell, J. (2014) · EMJ Nephrology · doi:10.33590/emjnephrol/10313322 · Cited by 1
Different Therapeutic Modalities for management of COVID-19
elmenshawy, S. M., Abdelsalam, M. H., Elnagdy, T., Elgohary, M. A., Sabri, N. A., & Elkhouly, A. (2024) · Archives of Pharmaceutical Sciences Ain Shams University · doi:10.21608/aps.2024.252694.1150 · Cited by 1
Fageräng, B., Götz, M. P., Cyranka, L., Lau, C., Nilsson, P. H., Mollnes, T. E., & Garred, P. (2024) · Journal of Innate Immunity · doi:10.1159/000539368 · Cited by 2
General Principles of Immunotherapy in Neurological Diseases
Rommer, P. S., Hecker, M., Zrzavy, T., & Zettl, U. K. (2024) · Springer eBooks · doi:10.1007/978-3-031-24297-7_12-1 · Cited by 2
Paroxysmal nocturnal hemoglobinuria: new concepts in pathophysiology and treatment
Weitz, I. C. (2015) · Orphan Drugs Research and Reviews · doi:10.2147/odrr.s73641 · Cited by 1
“It is thought that eculizumab inhibits the binding of C5 to the C3b-Bb-C3b complex (C5 convertase), blocking the conversion of C5 to C5a, C5b.64,65 Proximal C3b function is preserved.”
BackgroundInfluentialAnticorps monoclonal anti-C5 (éculizumab) dans l’hémoglobinurie paroxystique nocturne
Socié, G., Varoqueaux, N., & de Latour, R. P. (2009) · médecine/sciences · doi:10.1051/medsci/200925121126 · Cited by 1
“Il s’agit d’un anticorps monoclonal (Acm) inhibant le facteur C5 du complément [13].”
Novel Generation of Antibody-Based Therapeutics
Brezski, R. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-416603-5.00006-7 · Cited by 1
Ravulizumab in the treatment of paroxysmal nocturnal hemoglobinuria
Rho, H., & Wells, R. A. (2020) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2020.1804858 · Cited by 1
Matsuno, H., Hata, T., Takahashi, H., Haraguchi, N., Uemura, M., Nishimura, J., Takemasa, I., Mizushima, T., Yamamoto, H., Doki, Y., et al. (2019) · International Surgery · doi:10.9738/intsurg-d-14-00283.1 · Cited by 1
“Eculizumab, approved in 2007 by the US Food and Drug Administration, is a humanized monoclonal antibody that binds to the complement protein C5.(9,10) Eculizumab inhibits the terminal complement cascade, preventing complement-mediated haemolysis.”
BackgroundComplement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series
Vitkauskaitė, M., Vinikovas, A., Miglinas, M., Rimševičius, L., Čerkauskaitė, A., Mačionienė, E., & Ašakienė, E. (2022) · Clinical Case Reports · doi:10.1002/ccr3.5573
Membranoproliferative Glomerulonephritis and C3 Glomerulopathy in Children
Licht, C. P. B., Vivarelli, M., Khursigara, M. R., Pickering, M. C., & Walker, P. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-52719-8_29 · Cited by 4
The Case | A benign reason behind a malignant finding
Bharati, J., Bijol, V., Salvatore, S., Jhaveri, K. D., & Sharma, P. (2023) · Kidney International · doi:10.1016/j.kint.2022.08.016 · Cited by 1
A simple method to differentiate three classes of cholesterol-dependent cytolysins
Tomoyasu, T., Matsumoto, A., Takao, A., Tabata, A., & Nagamune, H. (2023) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2023.106696 · Cited by 1
The pathophysiology of paroxysmal nocturnal haemoglobinuria
Kelly, R. (2014) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York) · Cited by 1
Innovative Therapeutic Strategies in the Molecular Targeting Era
Nishimura, J. (2020) · Current Medicinal Chemistry · doi:10.2174/092986732725200619144223 · Cited by 1
(2012) · Elsevier eBooks · doi:10.1016/b978-1-907568-37-4.50029-4 · Cited by 1
A belt-and-suspenders approach to PNH
Gerber, G. F., & Brodsky, R. A. (2025) · Blood · doi:10.1182/blood.2024027600 · Cited by 1
Eculizumab: farmacología clínica
Jané, F. (2012) · Medicina Clínica
Mass spectrometry-based studies for the investigation of protein structure and dynamics
Edgeworth, M. J. (2026) · Warwick Research Archive Portal (University of Warwick) · doi:10.82444/warw.33696577
Arzneiverordnungen 2007 im Überblick
Schwabe, U. (2008) · Springer eBooks · doi:10.1007/978-3-540-69219-5_1
Moncharmont, P., Barraco, F., Bernaud, J., Raffin, A., Michallet, M., & Rigal, D. (2009) · Immuno-analyse & Biologie Spécialisée · doi:10.1016/j.immbio.2009.02.003
Hémoglobinurie paroxystique nocturne
Geffray, L. (2008) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2008.08.001
Complement: new therapies and emergence of the complotype
Morgan, B. P. (2013) · ISBT Science Series · doi:10.1111/voxs.12030
Ziakas, P. D., Kopterides, P., & Voulgarelis, M. (2010) · Current Vascular Pharmacology · doi:10.2174/157016110790226651
Anticorps anti-C5 dans l'hémoglobinurie
Varoqueaux, N. (2009)
Nieto‐Ríos, J. F., Serna-Higuita, L. M., Botero, E. C., Ocampo-Kohn, C., Aristizábal-Alzate, A., Zuluaga-Quintero, M., & Zuluaga-Valencia, G. A. (2016) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2016.01.008
O papel do sistema complemento no Síndrome Hemolítico Urémico Atípico
Luís, D. T. A. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/0r2h-6p64
13. Pathophysiology and Treatment of Marchiafava-Micheli Syndrome
Kanakura, Y. (2009) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.98.2349
[Topics of neuromyelitis optica].
Miyamoto, K. (2014) · Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology · doi:10.2177/jsci.37.468
Management of diagnosis and treatment in paroxysmal nocturnal hemogrobinuria
Nishimura, J., & Kanakura, Y. (2011) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.22.186
Risitano, A. M., Marando, L., Seneca, E., & Rotoli, B. (2011)
Etiology, Pathogenesis and Treatment in PNH.
Nishimura, J., & Kanakura, Y. (2011) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.100.1994
7. Progress in Treatment for Hematologic Diseases
Higashihara, M. (2014) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.103.717
Biologic Therapies In Systemic Lupus Erythematosus
Eisenberg, R. A. (2009) · CRC Press eBooks · doi:10.1201/9781420063219.ch4
Kanakura, Y., Ohyashiki, K., Shichishima, T., Okamoto, S., Ninomiya, H., Kawaguchi, T., Nakao, S., Nakakuma, H., Nishimura, J., Kinoshita, T., et al. (2013)
Monoclonal Antibodies for Musculoskeletal, CNS, and Other Diseases
Yie, J., & Wu, T. (2016) · Wiley eBooks · doi:10.1002/9781118940648.ch10
Metadata
- Authors
- Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L.
- Affiliations
- Alexion Pharmaceuticals (United States) (US)
- Johns Hopkins University (US)
- Corresponding author
- Rother, Russell P
- Venue
- Nature Biotechnology
- Published
- 2007-11
- Volume
- 25
- Issue
- 11
- Pages
- 1256-1264
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2004265876
- Cited by
- 778
- References
- 88
- Citations by year
- 2026: 34 · 2025: 38 · 2024: 43 · 2023: 58 · 2022: 34 · 2021: 47 · 2020: 59 · 2019: 49 · 2018: 42 · 2017: 52 · 2016: 60 · 2015: 39 · 2014: 41 · 2013: 38 · 2012: 43
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Update notices
- erratum (2007-12-01)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- eculizumab, paroxysmal nocturnal hemoglobinuria, complement inhibition, complement component C5, CD59, intravascular hemolysis, monoclonal antibodies, glycosylphosphatidylinositol deficiency, terminal complement activation, drug development
- MeSH terms
- Animals, Antibodies, Monoclonal, Clinical Trials as Topic, Complement C5, Drug Evaluation, Preclinical, Hemoglobinuria, Paroxysmal, Humans, Drug Design, Protein Engineering, Drug Approval, Complement Inactivating Agents, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.